Stock 4534 MOCHIDA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mochida Pharmaceutical Co., Ltd.

Equities

4534

JP3922800002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-01 am EDT 		5-day change 1st Jan Change
3,205 JPY +0.47% Intraday chart for Mochida Pharmaceutical Co., Ltd. +1.26% -1.99%
Apr. 25 Hidehiro Imatsu named president of Goldman Sachs Japan RE
Mar. 21 Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hidehiro Imatsu named president of Goldman Sachs Japan
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1%
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 30, 2023
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million.
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Idorsia schliesst erstes Halbjahr 2021 etwas besser als erwartet ab
Idorsia schliesst erstes Quartal 2021 besser als erwartet ab
Idorsia senkt 2020 Ausgaben stärker als erwartet
Idorsia schreibt nach neun Monaten weniger Verlust
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4534 Stock
  4. News Mochida Pharmaceutical Co., Ltd.
  5. Other languages